JLJames Lucas

James Lucas

*This is an algorithmically generated author record based on publicly available information.

James Lucas has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Post-Pandemic Burden of Illness Among Patients in Germany Aged ≥60 Years with Acute or Persistent COVID-19

    by Mousumi Biswas, James Lucas, Tendai Mugwagwa, Eveline Otte Im Kampe, Mohammad Ashraf Chaudhary, Abid Kabir, Emily Quinones, James Piercy, Ruth Mokgokong

    Background/Objectives: Post-pandemic, real-world evidence on COVID-19 in elderly patients in Germany is limited. This study describes the clinical characteristics, treatment patterns, quality of life, and healthcare resource use among elderly patients with COVID-19. Methods: Data were derived from the Adelphi Real World COVID Disease-Specific Programme™, a cross-sectional survey of physicians and patients aged ≥60 years with acute (≤4 weeks post-diagnosis) or persistent (symptom duration ≥ 12 weeks) COVID-19 from January to July 2024. Analyses were descriptive; comparisons between groups were not performed. Results: 151 physicians provided data for 400 patients (acute COVID-19, n = 200; persistent COVID-19, n = 200). The mean patient age was 68.1 (acute) and 70.1 (persistent) years. Most patients were male (acute, 56.0%; persistent, 58.5%) and retired (acute, 68.0%; persistent, 78.5%). The most common concomitant condition was hypertension (acute, 37.5%; persistent, 35.5%). Tiredness/fatigue was the most common physician-reported symptom (57.5% acute; 67.5% persistent). For patients with acute COVID-19 that received prescribed treatment (n = 62/200, 31.0%), antivirals were most commonly used (n = 59/62, 95.2%). Mean number of consultations from the index COVID-19 diagnosis to survey date was 2.7 over a median of 17.0 days (Q1–Q3: 7.0–44.0) and 5.0 over a median of 164.0 days (Q1–Q3: 128.0–225.0) for patients with acute or persistent COVID-19, respectively. Self-reported data were provided by 98 (acute) and 107 (persistent) patients. The most common patient-reported worst symptoms were headaches (n = 15/98, 15.3%; acute) and tiredness (n = 14/107, 13.1%; persistent). Mean EQ-5D-5L index score (German weighting) was 0.79 for both groups. EQ-VAS scores were 66.1 (acute) and 66.0 (persistent). Conclusions: Elderly patients with acute or persistent COVID-19 have a notable burden of illness. Prioritizing care and interventions in these populations in the post-pandemic era is warranted.

  • Open Access

    Treatment patterns and clinical burden in adults and children with plaque psoriasis: a real-world survey

    by Elizabeth (Lisa) Swanson, William Malatestinic, James Lucas, James Hetherington, Najwa Somani, Russel Burge, Bruce Konicek

  • Open Access

    The Clinical and Symptomatic Burden Among Older Adults with Respiratory Syncytial Virus: A Real-World Survey in Five European Countries

    by Diana Mendes, James Lucas, Emily Quinones, Mayesha Chowdhury, Libby Turner, Stéphane Fiévez, Caroline Lade, Roberto Di Virgilio, Alejandra López-Ibáñez de Aldecoa, James Piercy, et al.

    Introduction Although respiratory syncytial virus (RSV) is a common cause of respiratory illness in older adults (≥ 60 years), data on overall burden remain limited. This study investigated the clinical and symptomatic burden in older adults with RSV in Europe. Methods Data were drawn from the Adelphi RSV Disease Specific Programme (DSP)™, a cross-sectional survey of physicians and their patients with RSV, conducted across Europe between Q4 2023–Q2 2024. Physicians reported demographics, clinical characteristics, symptoms, disease progression, comorbidities, and impact on health-related quality of life (HRQoL) and activities of daily living (ADL). Patients self-reported HRQoL via the Respiratory Infection Intensity and Impact Questionnaire (RiiQ™) and EQ-5D-5L. Patients were grouped as: A-RSV (Acute, symptom onset 0-< 4 weeks), O-RSV (Ongoing, symptom onset 4-< 12 weeks), P-RSV (Post-acute, symptom onset 12-≤ 52 weeks) and H-RSV (Post-hospital discharge, symptom onset ≤ 52 weeks). Results Overall, 602 physicians reported data on 1581 patients (n = 237 A-RSV, n = 196 O-RSV, n = 588 P-RSV, n = 560 H-RSV). Of those with H-RSV, 34.1% were aged 75 + (A-RSV: 20.7%) and 58.7% had 3 + concomitant conditions (A-RSV: 29.2%) at diagnosis. RSV affected patients’ HRQoL and ADL, psychological well-being, relationships and ability to support/care for family members, with differences observed across groups, particularly in patients with H-RSV (all p < 0.01). Of the 417 (26.4%) patients who self-reported HRQoL, differences across RiiQ™ symptom scores were observed (all p < 0.05), indicating higher burden in the A-RSV and H-RSV groups. Differences in overall EQ-5D-5L scores and in the EQ-5D mobility, self-care and anxiety/depression domains were also significant (all p < 0.05). Conclusions RSV was associated with high burden. Patients experienced a high symptom burden, and patients with O-RSV, P-RSV and H-RSV experienced persistent symptoms over a long duration post-infection. Patients reported poor HRQoL across all outcome measures. Given this burden, focus on preventive measures such as RSV vaccination should be prioritized.


  • Open Access

    Resource use and economic burden of respiratory syncytial virus among older adults in real-world clinical practice across five European countries

    by Diana Mendes, James Lucas, Emily Quinones, Katherine Li, Stephane Fievez, Caroline Lade, Roberto Di Virgilio, Alejandra López-Ibáñez de Aldecoa, James Piercy, Tim Holbrook, et al.

    Introduction: The impact of respiratory syncytial virus (RSV) is increasingly being recognized in older adults, however economic burden data is sparse. This study describes the burden of RSV and associated direct and indirect costs in adults aged 60 + years in real-world clinical practice across five European countries. Methods: Data were drawn from the Adelphi RSV Disease Specific Program (DSP™), a cross-sectional survey of physicians and patients in France, Germany, Italy, Spain, and the United Kingdom conducted December 2023–June 2024. Patients aged 60 + with a confirmed RSV diagnosis were included. Physicians provided data on resource use and supportive care needs, and patients on paid and unpaid productivity loss. Country-specific unit costs were used to calculate direct and indirect costs. Patients were stratified by symptom duration from onset (acute- [A-]RSV: n = 682) provided data on 1,581 patients with RSV (15.0% A-RSV, 12.4% O-RSV, 37.2% P-RSV, and 35.4% H-RSV). For their current RSV infection, patients had a mean of 4.3 visits to any healthcare provider (A-RSV: 3.1–H-RSV: 4.6). H-RSV patients received nearly four times as many tests as A-RSV patients, with 54.8% receiving drugs (versus n = 24), with 18.0% of the 373 patients who responded reporting unpaid productivity loss. Mean direct costs per patient ranged from €320–€6,900 for A-RSV and H-RSV respectively, with hospitalization driving costs in H-RSV. Drug costs trended higher with disease duration. The indirect cost of supportive care was consistent across groups (€140–€191), meanwhile paid productive loss cost was between €52–€797 and unpaid productivity loss between €25–€415 in A-RSV and P-RSV, respectively. Conclusion: RSV poses a high economic burden in older adults across disease stages, increasing numerically with symptom duration and need for hospitalization, highlighting a need for prevention and continued monitoring.


  • Open Access

    Patient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study)

    by Emily J. Goddard, James M. Haughton, James E. Lucas, Sophie G. Barlow, Timothy P. Fitzgerald, Alexander M. Litvintchouk, David Wu

    Introduction Psoriasis (PsO) is a common dermatological condition. Psoriasis severity is commonly characterized by percentage body surface area (BSA) affected, with < 3% BSA considered mild disease and 3–10% moderate disease. Treatment options for and knowledge of clinical practice patterns in patients with mild PsO are limited. Here, we use real-world data to characterize patients diagnosed with mild and moderate PsO and their clinical management. Methods Data were derived from the Adelphi Real World PsO Disease Specific Programme™, a cross-sectional survey of dermatologists and adult patients with PsO in the USA, between December 2021 and March 2022. Dermatologists reported demographic and clinical details. Patients reported treatment satisfaction and quality of life using patient-reported outcome measures. Patients were stratified by physician-reported severity at diagnosis (mild/moderate) and compared using bivariate analyses. Results Out of 389 patients, 18.5% were diagnosed with mild PsO. The majority were female, white, and employed. Patients diagnosed with moderate PsO had higher body mass index (p = 0.002) and longer disease duration (p = 0.041). Only 22.0% of patients diagnosed with mild PsO had BSA < 3% at diagnosis, and 48.1% of patients diagnosed as moderate PsO had BSA < 10%. BSA improvement following initiation of current treatment was higher among patients diagnosed with moderate PsO (p < 0.001). Those diagnosed with moderate PsO more commonly had involvement of the elbows (p = 0.003), legs (p = 0.002), knees (p < 0.001), soles (p = 0.035), and back (p = 0.004) at diagnosis. Cracked skin, redness, and tender skin (p < 0.001 for all) were more common among those diagnosed with moderate PsO. Both groups mostly received topical agents; however, those diagnosed with moderate PsO more commonly received systemic (p < 0.001) or biologic (p = 0.002) treatment. Patients diagnosed with moderate PsO had lower EQ-5D-5L (p = 0.014) and treatment satisfaction (p = 0.007) scores. Conclusion These findings suggest that physicians routinely underestimate PsO severity, resulting in possible undertreatment, suboptimal outcomes, and quality-of-life impairments for patients with milder severity PsO.


  • Open Access

    Suboptimal Clinical and Quality of Life Outcomes in Patients with Psoriasis Undertreated with Oral Therapies: International Physician and Patient Survey

    by Sydney Thai, Sophie Barlow, James Lucas, James Piercy, Yichen Zhong, Joe Zhuo, Jashin J. Wu

    Introduction Psoriasis is a chronic, inflammatory, immune-mediated disease. This study assessed the time at which patients switched from a conventional oral systemic treatment to a biologic therapy; patient clinical and quality of life (QoL) outcomes associated with oral systemic treatments; and the proportion of patients who persisted on oral therapy (nonswitchers), despite reported suboptimal clinical and QoL outcomes. Methods This data analysis used the Adelphi Real World Psoriasis Disease Specific Programme, a non-interventional, retrospective, cross-sectional survey conducted in the USA, France, Germany, and United Kingdom (August 2018–April 2019). Kaplan–Meier (KM) analysis assessed switching from oral to biologic therapy in patients treated ≥ 3 years at survey completion (n = 597). The severity of psoriasis was reported by physicians as the percentage of body surface area (BSA) affected by psoriasis. Dermatology Life Quality Index (DLQI) scores were calculated for three groups: nonswitchers who met treatment failure criteria, nonswitchers who did not meet failure criteria, and switchers to a biologic therapy. Results In KM analysis, approximately 50% of the patient population switched by 24 months. A substantial portion of nonswitchers continued to have moderate-to-severe psoriasis. Among nonswitchers, 57–77% had BSA ≥ 3% and 16–24% had BSA ≥ 10% at the time of the survey compared with 37% of switchers who had BSA of ≥ 3% and 9% who had BSA of ≥ 10%. QoL was poor among nonswitchers. The mean [standard deviation (SD)] DLQI scores for nonswitchers meeting treatment failure criteria, nonswitchers not meeting failure criteria, and switchers were 6.11 (4.55), 2.62 (3.29), and 2.25 (4.23), respectively. Conclusion There is a clear unmet need for more effective oral therapies, and further research into the reasons for patients remaining undertreated, which may include patient preference for oral treatments (despite lack of response), contraindications, or insurance/formulary-related barriers to access, are needed. Graphical Abstract


  • Real-world health outcomes in US adult patients with mild to moderate plaque psoriasis taking topical therapy

    by David Kaplan, James Hetherington, James Lucas, Ibrahim Khilfeh, Tara Nazareth

    Limited health outcomes information exists for patients with mild to moderate plaque psoriasis (hereafter, referred to as psoriasis) prescribed topical treatment(s).We evaluated clinical characteri...


  • Open Access

    Patient Characteristics and Treatment Patterns in European Pediatric Patients with Psoriasis: A Real-World, Cross-Sectional Study

    by Michael Sticherling, Tess McPherson, Raúl de Lucas Laguna, Antonio Costanzo, Catherine Reed, Esther Artime, Camille Robert, James Lucas, Christopher Schuster, Emmanuel Mahé

    Introduction This study evaluated patient characteristics and treatment patterns according to weight in pediatric patients with psoriasis in a real-world setting. Methods Primary care and specialist physicians treating pediatric patients with psoriasis aged 6–17 years in five European countries were surveyed in the 2019–2020 Adelphi Real World Pediatric Psoriasis Disease Specific Programme. At least two patients with current or previous biologic use were included per physician. Patient characteristics and treatment patterns were analyzed overall and for patients weighing 25–50 kg or more than 50 kg. Results Data from 772 patients weighing 25–50 kg and 1147 weighing more than 50 kg were analyzed. Median age at diagnosis was significantly less in lighter than heavier patients (10.0 vs. 14.0 years; p < 0.001), as was median disease duration (2.2 vs. 3.0 years; p < 0.001). Topical treatments were prescribed in 59.0% of patients overall (70.3% of lighter and 51.4% of heavier patients; p < 0.001), and were used to treat mild rather than moderate-to-severe psoriasis. Conventional systemic use was low (10.8% of patients overall) and predominantly for moderate-to-severe psoriasis. In this biologic-enriched sample, most biologics (78.2%) were prescribed in older (> 13 years) patients. Biologic use increased with line of therapy (6.6% of first-line, 18.0% of second-line, 33.7% of third-line, 44.7% of fourth-line treatments). Conclusion Biologics are predominantly prescribed in older (> 13 years) and heavier (> 50 kg) patients, with little first- or second-line use. The low use of biologics in European pediatric patients with psoriasis may represent an unmet treatment need, as topical or conventional systemic agents remain the main treatment option for moderate or severe psoriasis in these patients through the treatment pathway.


  • Open Access

    Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: A US and EU Real-world Evidence Study

    by Marieke M.B. Seyger, Matthias Augustin, Michael Sticherling, Teresa Bachhuber, Juanzhi Fang, James Hetherington, James Lucas, Sophie Meakin, Craig Richardson, Amy S. Paller

    This study is a retrospective analysis using data collected from the Adelphi Paediatric Psoriasis Disease-Specific Programme cross-sectional survey. Despite being treated for their psoriasis, a substantial proportion of paediatric patients presented with moderate (18.3%) or severe (1.3%) disease at sampling; 42.9% and 92.0% had a body surface area (BSA) of >10%, and 38.8% and 100.0% had a Psoriasis Area Severity Index (PASI) score >10, respectively. Overall, 69.9% of patients had only ever been treated with a topical therapy for their psoriasis. For patients with moderate or severe disease at sampling, 16.3% and 14.4% were currently receiving conventional systemics or biologic therapy, respectively. There is a clinical unmet need in this paediatric population; a considerable percentage of patients still experienced moderate or severe disease and persistent psoriasis symptoms, with numerous body areas affected. A significant proportion of patients were undertreated, which may explain the high burden of disease observed.


  • 26918 Describing real-world pediatric psoriasis patients in the US and EU5

    by Nadine Chapman-Rothe, Craig Richardson, Amie Scott, Haijun Tian, Fetske Van Der Meulen, Teresa Bachhuber, Steve Lobosco, James Lucas, Sophie Meakin, James Hetherington, et al.